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 Introduction 
 Sleep is strongly associated with daily well-being and 
functioning  [1] , learning capacity and academic perfor-
mance  [2] . Chronic sleep disturbances decrease physi-
cal and psychological functioning in both adolescents
 [3] and adults  [1] . Furthermore, sleep complaints and
insomnia in adults seem to be on the increase world -
wide  [4, 5] .
 Amongst the variety of possible factors adversely af-
fecting sleep, for several reasons, depressive disorders 
and restless legs syndrome (RLS) demand particular at-
tention. First, depressive and sleep disorders are highly 
associated  [6–11] . Second, poor sleep is predictive of fur-
ther episodes of depressive disorders  [12] .
 The relation between RLS and depressive symptoms 
(DS) is complex but appears to be common; overlapping 
symptoms include deteriorated sleep, decreased mood 
and daily functioning, daytime fatigue, reduced atten-
tion, decreased libido  [8] and daytime sleepiness  [13] . 
RLS is considered a distressing sensorimotor disorder oc-
curring with 5–10% of prevalence in the USA and other 
Western countries  [8, 14, 15] , and alterations in iron-do-
pamine connections have been considered in its etiology 
 [16, 17] . In contrast, depressive disorders are seen as forms 
of mental disorder caused by biological (e.g. dysfunction-
al neuronal activity  [18] ), psychological (e.g. dysfunction-
 Key Words 
 Depressive symptoms   Major depressive disorders   
Restless legs syndrome   Polysomnography   Sleep 
disorders 
 Abstract 
 Background: Depressive disorders and restless legs syn-
drome (RLS) demand particular attention because sleepi-
ness, daytime fatigue and loss of interest are symptoms at-
tributable to both depressive disorders and RLS. Moreover,
a high comorbidity rate is observed. The aim of the present 
study was to compare polysomnographic data of patients 
suffering from RLS, RLS and depressive symptoms, and major 
depressive disorders (MDD).  Methods: Sleep EEG recordings 
of patients suffering from RLS (n = 25), RLS and depressive 
symptoms (n = 38), as well as MDD (n = 15) were compared. 
 Results: Compared to patients with MDD, both groups with 
RLS had statistically decreased values of sleep continuity, in-
cluding sleep efficiency, sleep onset latency and wakening 
after sleep onset. Patients with RLS or RLS and depressive 
symptoms had also decreased slow-wave sleep compared to 
patients with MDD.  Conclusions: Objective sleep assessment 
supports previous findings: RLS is a disorder seriously affect-
ing sleep, even compared to MDD. Concomitant symptoms 
of depression do not seem to additionally deteriorate sleep, 
though they trigger differences in treatment. 
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al thoughts  [19] ) and social (lack or dearth of or dissatis-
fying social feedback  [20] ) factors.
 In patients suffering from RLS, light sleep (stages 1 and 
2) is increased; slow-wave sleep (SWS; stages 3 and 4) and 
rapid eye movement (REM) sleep are decreased, with de-
layed sleep onset and REM latency  [21, 22] . As a conse-
quence, sleep is nonrestoring. Furthermore, a common 
neurobiological cause for both RLS and sleep disturbanc-
es has not been detected so far  [23] . In contrast, for depres-
sive disorders, there is evidence that sleep is impaired due 
to altered neuroendocrine activity, leading to markedly 
shortened REM sleep latency, increased REM sleep and 
REM density, as well as poor sleep efficiency (cf.  [12] ).
 Despite their different etiologies, co-occurrence of 
RLS and DS is often observed (cf.  [7–11] ), though the di-
rection of the relation is complex. There is evidence that 
the onset of RLS often precedes the onset of depressive or 
other psychiatric disorders. For example, Winkelmann et 
al.  [10] reported that the lifetime prevalence rates for ma-
jor depression also exceeded controls [36.9 vs. 15.2%; 
odds ratio (OR) = 3.30, 95% CI = 2.1–5.0], with the major-
ity (76.7%) reporting the onset of depression after that of 
RLS. Furthermore, 83.3% of the patients with dysthymia, 
63.6% of those with general anxiety disorders and 60% of 
those with panic disorder reported the occurrence of RLS 
before the onset of the psychiatric disorder. Moreover, 
treatment of RLS with dopaminergic agents leads to 
markedly reduced DS  [24] .
 Given these considerations, one might ask to what ex-
tent sleep is impaired in patients suffering from RLS and 
concomitant DS. Surprisingly, no study has compared 
polysomnographic data from patients suffering from 
RLS, and RLS and DS, with those of patients suffering 
from major depressive disorders (MDD). The aim of the 
present study was therefore to gain a deeper insight into 
the nature of the polysomnographically recorded sleep of 
patients with RLS alone or RLS in combination with DS, 
if compared to the sleep of patients suffering from MDD. 
We hold that the results may be important for further ac-
curate treatment of patients with RLS.
 We formulated the following 3 hypotheses. First, fol-
lowing previous research (e.g.  [12, 21, 22] ), we expected 
increased REM sleep latency, decreased REM sleep and 
less SWS in patients with RLS when compared to patients 
suffering from MDD. Second, following Coccagna and 
Luganesi  [21] , we anticipated more awakenings and more 
light sleep (stages 1 and 2) in patients suffering from RLS, 
again compared to those with MDD. Third, given that DS 
and RLS show a high overlap in symptomatology (cf.  [8, 
13] ), we expected higher rates of antidepressant medica-
tion in patients suffering from both RLS and DS, when 
compared to the rates for those suffering from RLS with-
out DS.
 Moreover, we explored to what extent differences with 
respect to sleep, periodic limb movements (PLMs) and 
arousals between patients suffering from RLS with or 
without DS might emerge and to what extent these 2 
groups also differ from patients suffering from MDD. Put 
in other terms: we explored if the combination of RLS
and DS may have additive effects leading to an increase 
in sleep deterioration compared to patients suffering ex-
clusively from RLS and patients with MDD.
 Methods 
 Sample and Procedure 
 A total of 78 patients [41 females, 37 males; mean age = 51.66 
years (SD = 12.89)] took part in the study. Of those, 25 were pa-
tients suffering from RLS [mean age = 53.32 years (SD = 16.23); 9 
female and 16 male patients; labeled the ‘group with RLS’]; 38 
were patients suffering from both RLS and DS [mean age = 50.20 
years (SD = 14.42); 21 female and 17 male patients; labeled the 
‘group with RLS and DS’]; and 15 were patients suffering from 
MDD [mean age = 51.47 years (SD = 8.04); 11 females and 4 males; 
labeled the ‘group with MDD’]. The 3 groups did not differ with 
respect to gender [X 2 (2) = 5.46, p = .07) 1 nor with respect to age: 
[F(2, 75) = 0.37, p = 0.69].
 The procedure was as follows: for patients suffering from RLS, 
patients complaining about poor, nonrestoring sleep were entered 
in the sleep research unit (SRU) on referral. Then, a semistruc-
tured interview was conducted by a professional and experienced 
psychiatrist (M.H.). This covered sleep history, psychiatric exam-
ination according to the DSM-IV criteria  [25] and current medi-
cation; physical examination and laboratory chemistry were per-
formed afterwards. For polysomnographic recording, the pa-
tients slept in the SRU for 1 night. When the data elaboration was 
completed, the results were interpreted and explained to the pa-
tients. Afterwards, a rationale for therapy treatment was decided 
on and therapy was initiated.
 For patients suffering from MDD, a structured clinical inter-
view (SCID;  [26] ), including also items related to RLS and PLMs, 
was conducted. Patients suffering form MDD were also part of an 
ongoing study. This sample has already been largely described in 
Hatzinger et al.  [12] . For short, after a washout phase of 1 week, 
all the 15 patients were treated with trimipramine monotherapy 
for 6 consecutive weeks. Sleep  electroencephalography (EEG) re-
cordings were performed 1 week after the beginning of treatment 
with trimipramine.
 The local ethics committee approved the study.
 1  Descriptively, gender distribution was not balanced. For this reason, 
preliminary computations were performed with gender as covariate. How-
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 Materials 
 Assessing RLS during Diagnostic Interview 
 Following Walters  [27] , Shapira  [28] and Allen et al.  [6] , a di-
agnosis of RLS was given if a patient answered ‘yes’ to the follow-
ing 4 questions: (i) do you feel an urge to move the legs, normally 
accompanied by uncomfortable and unpleasant leg sensations; 
(ii) do symptoms worsen when lying or sitting; (iii) are symptoms 
at least partially relieved by movement, and (iv) are symptoms 
worse in the evening or at night?
 Assessing Sleep and RLS with Polysomnography 
 All patients slept in the SRU for 1 night. Sleep was recorded 
between 11 p.m. (lights off) and 7 a.m. (lights on) using standard 
procedures of polysomnography: horizontal electro-oculogra-
phy, submental myography and EEG (C3–A2, C4–A1, C3–C4) as 
well as electrocardiography. The sleep records were visually 
scored by 2 experienced raters according to standardized criteria 
 [29] . Twenty percent of the sleep records were independently dou-
ble-checked. The interrater reliability was r = 0.92. The sleep pa-
rameters were analyzed according to the definitions in the stan-
dard program described by Lauer et al.  [30] . In addition to the 
common sleep variables, for patients suffering from RLS, the 
PLM index and arousals were assessed.
 Assessing PLMs 
 Following the Atlas Task Force  [31] , we labeled a PLM if se-
quences of extensions or flexions of lower limbs occurred at least 
4 times consecutively for  1 5 s, if the intervals lasted not more than 
90 s, and if the interval between the sequences lasted between 20 
and 40 s. To assess PLMs, a movement electrode linked with the 
sleep EEG recorder was placed on both legs.
 Assessing DS 
 An MDD was diagnosed if during the SCID (German version: 
 [26] ) a patient indicated to suffer severely from changes in behav-
ior, cognition and emotion such as disturbed sleep, loss of motiva-
tion and interest, withdrawal from social activities and contacts, 
difficulties in concentrating, feelings of being guilty and worth-
less, or decreased or increased weight. DS were diagnosed if a pa-
tient indicated to suffer a little to moderately from the changes in 
behavior, cognition and emotion described above.
 Pretreatment with Medication 
 This diagnostic interview also covered current medication in-
take (see  table 1 ). Daily clinical experience shows intake of dif-
ferent medications in people suffering from sleep disturbances. 
Thus, before performing definitive statistical analyses, we ex-
plored the possibility that sleep values might be biased because 
of drug pretreatment (see  table 1 for overview). To this end, we 
compared the sleep values for patients pretreated with sleep-in-
fluencing medicaments with those of patients without drug 
treatment or taking medication without any influence on sleep. 
Ten (40%) of the 25 patients in the RLS group were pretreated 
with sleep-altering medicaments; the sleep value means did not 
differ significantly (all t  ! 1). Twenty-eight (73.7%) of the 38 pa-
tients  suffering from RLS and DS were pretreated with sleep-al-
tering medicaments; again, the mean sleep values did not differ 
significantly (all t  ! 1). We also explored the possibility that dif-
ferent types of medication could alter sleep continuity and sleep 
architecture in different directions, leading to possible zero-ef-
fects of mean values; however, this was not the case. Therefore, it 
was not necessary to perform subsequent statistical analyses con-
trolling for medication, nor were data from individual patients 
excluded from further analyses.
 Patients suffering from MDD were treated with a monothera-
py of trimipramine.
 Statistical Analyses 
 The gender distributions of the 3 groups were compared with 
a   2 test. Mean differences in sleep variables were calculated
with one-way ANOVAs, and post-hoc tests were performed after 
Games-Howell. For exploratory and descriptive reasons, post-hoc 
tests were also reported for ANOVAs without significant p values. 
The post-hoc procedure after Games-Howell is readily applicable 
where group sizes are unequal; furthermore, homogeneity of vari-
ances is not mandatory  [32] .   2 tests and OR calculations were 
Table 1. Patients suffering from RLS with or without DS, and with or without sleep-altering medications
Medications
medications altering sleep no medication or medication not altering sleep
Group with RLS
(n = 25)
n = 10 n = 15
benzodiazepines (3), methylphenidate (1), trimipramine (1), 
amitriptyline (1), trazodone (1), pramipexole (1), levodopa (1)
12 patients without any medication, aspirin (2),
products against heart disease (5)
Group with RLS
and DS (n = 38)
n = 28 n = 10
benzodiazepines (7), trimipramine (7), fluoxetine (1), sertra-
line (1), amitriptyline (1), escilatropram (4), mianserin (2), 
paroxetine (4), trazodone (2), reboxetine (2), mirtazapine (1), 
zopiclone (1), zolpidem (1), venlafaxine (1), pramipexole (1), 
levodopa (2), lamotrigine (1), risperidone (2), quetiapine (1)
7 patients without any medication,
cardiovascular medications (3)
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performed to explore the distribution of antidepressant medica-
tion between the groups of patients suffering from RLS with or 
without DS. Correlations were performed using Pearson’s r (2-
tailed). Test results with an   -error below 0.05 are reported as sig-
nificant. Analyses were conducted using SPSS 15.0 for Windows.
 Results 
 Sleep continuity, sleep architecture and REM sleep 
were compared between the groups with RLS, with RLS 
and DS, and with MDD.
 Sleep Continuity 
 Table 2 provides an overview of the descriptive and 
inferential statistics with respect to sleep continuity.
 Significant mean differences were observed for time 
in bed, sleep period time, total sleep time and sleep effi-
ciency. No statistically significant mean differences were 
observed for wakening after sleep onset and sleep onset 
latency. Post-hoc analyses showed that there were no 
mean differences between the group with RLS and the 
group with RLS and DS. Compared to the group with 
MDD, the group with RLS showed decreased values with 
respect to total sleep time and sleep efficiency, whereas 
the group with RLS and DS showed decreased values with 
respect to time in bed, sleep period time, total sleep time, 
sleep efficiency, wakening after sleep onset and sleep on-
set latency.
 In sum, compared to patients suffering from MDD, 
patients with RLS did show more unfavorable values of 
sleep continuity.
 Sleep Architecture 
 Table 3 provides the overview of the descriptive and 
inferential statistics with respect to sleep architecture.
 Significant mean differences between the groups with 
RLS, RLS + DS and MDD were observed for stage 3 (min-
utes) and for SWS, whereas for all other dimensions re-
lated to sleep architecture no significant mean differenc-
es were found.
 For stage 3 sleep, post-hoc analyses revealed that the 
groups with RLS (with/without DS) did not differ, where-
as both RLS groups showed significantly decreased val-
ues compared to the group with MDD. For SWS, a similar 
pattern of results was found, although the difference be-
tween the RLS with DS group and the MDD group did 
not quite reach statistical significance.
 Taken together, compared to patients suffering from 
MDD, those with RLS had decreased stage 3 and SWS.
 REM Sleep 
 Table 4 provides an overview of the descriptive and 
inferential statistics with respect to REM sleep.
 Significant mean differences between the groups RLS, 
RLS + DS and MDD were found for the REM sleep time 
(minutes, percent) and the REM sleep latency (minutes). 
Post-hoc analyses showed that the RLS groups did not 
differ from each other, whereas both the group with RLS 
and the group with RLS + DS did differ from the group 
with MDD, with significantly less REM sleep (minutes) 
and with a significantly increased REM sleep latency.
Table 2. Statistical overview of sleep continuity in patients suffering from RLS, from RLS and DS and from MDD















TIB, min 480.00854.00 449.63873.05 510.27840.39 (21, 75) = 5.48, 0.006 0.110 0.140 0.001
SPT, min 438.80887.54 400.00894.45 482.6839.73 (2, 75) = 5.42, 0.006 0.248 0.092 0.000
TST, min 360.92895.25 331.268108.88 453.00860.99 (2, 75) = 8.45, 0.001 0.490 0.002 0.000
SE TST/SPT, % 82.98815.33 82.61819.27 93.6487.98 (2, 75) = 2.99, 0.005 0.998 0.017 0.013
WASO, min 89.65882.73 77.38870.34 38.00836.55 (2, 75) = 2.49, 0.092 0.830 0.086 0.004
SOL, min 29.8850.46 41.72858.22 13.17812.63 (2, 75) = 1.78, 0.175 0.670 0.275 0.019
TIB = Time in bed; SPT = sleep period time; TST = total sleep time; SE = sleep efficiency; WASO = wakening after sleep onset;
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Table 3. Statistical overview of sleep architecture in patients suffering from RLS, from RLS and DS and from MDD
Variables Goups Statistical analyses








Stage 1, min 45.78836.98 41.76829.51 37.47818.89 (2, 75) = 0.36, 0.701 0.890 0.620 0.810
Stage 1, % 12.91811.69 16.28821.92 8.7285.59 (2, 75) = 1.12, 0.333 0.710 0.290 0.130
Stage 2, min 281.528194.30 238.59872.05 256.23843.69 (2, 75) = 0.93, 0.400 0.550 0.810 0.530
Stage 2, % 78.94849.95 75.85826.82 56.5686.38 (2, 75) = 2.26, 0.112 0.960 0.089 0.000
Stage 3, min 12.33816.44 20.53830.41 38.37821.11 (2, 75) = 5.11, 0.008 0.360 0.001 0.049
Stage 3, % 3.2884.29 8.97817.57 8.3484.55 (2, 75) = 1.60, 0.210 0.148 0.004 0.980
Stage 4, min 8.06818.23 8.76817.16 11.9814.64 (2, 75) = 0.26, 0.775 0.990 0.750 0.780
Stage 4, % 1.9784.22 4.48813.76 2.5183.08 (2, 75) = 0.52, 0.593 0.550 0.890 0.690
SWS, min 20.38829.90 29.29841.59 50.27831.38 (2, 75) = 3.20, 0.046 0.590 0.016 0.130
SWS, % 5.2587.27 13.44829.09 10.8686.59 (2, 75) = 1.15, 0.325 0.230 0.045 0.860
For exploratory and descriptive reasons, post-hoc tests were performed even if an ANOVA was not significant.
Table 4. Descriptive and statistical overview of REM sleep in patients suffering from RLS, from RLS and DS and from MDD
Variables Groups Statistical analyses








REM sleep, min 62.09832.79 54.74830.36 98.37836.02 (2, 75) = 10.04, 0.000 0.646 0.010 0.001
REM sleep, % 16.5686.99 15.7988.55 21.4486.67 (2, 75) = 3.09, 0.045 0.920 0.050 0.041
REM latency, min 133.14893.64 134.67871.08 71.97830.69 (2, 75) = 4.21, 0.019 0.990 0.014 0.000
For exploratory and descriptive reasons, post-hoc tests were performed even if an ANOVA was not significant.
Table 5. Correlations between PLM index and arousals in patients suffering from RLS
Sleep variables
sleep continuity sleep architecture REM sleep
TIB SPT TST SE WASO, min WASO, % SOL S1 S2 S3 S4 S4 SWS REM-S
PLM index –0.25* –0.37** 0.33* 0.42**
Arousal –0.37** –0.35** –0.53** 0.39* 0.43**
TIB = Time in bed; SPT = sleep period time; TST = total sleep time; SE = sleep efficiency; WASO = wakening after sleep onset;
SOL = sleep onset latency; S = stage.
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 Antidepressant Medication in Groups with RLS 
 Patients with RLS and DS received more antidepres-
sants than those with RLS without DS [X 2 (1) = 13.36, p = 
0.000]. OR showed that RLS patients with DS were 20 
times more likely to receive antidepressants than RLS pa-
tients without DS (OR = 19.44; 95% CI = 3.19–118.40).
 PLM Index and Arousals in Patients Suffering from 
RLS 
 To explore the association between PLM index and the 
number of arousals and other sleep variables in patients 
suffering from RLS, several correlations were computed 
(see  table 5 ). First, we compared the PLM index and 
arousals across the 2 groups (i.e. RLS groups with or 
without DS) to determine whether they should be consid-
ered separately. However, neither the means for the PLM 
index [RLS group with DS: M = 27.87, SD = 25.46; RLS 
group without DS: M = 34.41, SD = 32.32; t(59) = 0.88,
p = 0.382], nor the mean number of arousals [RLS group 
with DS: M = 12.17, SD = 18.85; RLS group without DS: 
M = 9.53, SD = 5.03; t(59) = –0.65, p = 0.516] differed sig-
nificantly. Therefore, separate analyses were not per-
formed.
 Table 5 provides the correlation matrix between sleep 
variables, PLM index and arousals in patients suffering 
from RLS.
 The general pattern of results suggests that both the 
PLM index and arousals are negatively associated with 
the duration and the onset of sleep, whereas values re-
lated to sleep architecture and REM sleep were not sig-
nificantly associated.
 Discussion 
 The key findings of the present study are that, com-
pared to patients suffering from MDD, patients with RLS 
show a particular pattern of polysomnographically mea-
sured impaired sleep, and that patients suffering from 
RLS with or without DS do not differ from each other 
with respect to sleep, but concerning premedication.
 Three hypotheses were initially formulated and each 
of these is considered in turn.
 With the first hypothesis we expected increased REM 
sleep latency, decreased REM sleep and decreased SWS 
in patients with RLS when compared to patients suffering 
from MDD. The hypothesis was fully confirmed: patients 
with RLS showed a decreased REM sleep and REM sleep 
latency compared to those suffering from MDD. This 
pattern of results fits well with a wealth of previous re-
search findings (cf.  [7–12, 22] ). Moreover, patients with 
RLS did also show a statistically decreased stage 3 and 
SWS. Thus, whereas in patients suffering from MDD the 
SWS/REM sleep ratio was in favor of REM sleep due to 
the underlying neuroendocrine regulation of increased 
CRF and cortisol (see Hatzinger et al.  [12] ), it does not 
seem conceivable to implicitly deduce that in patients 
suffering from RLS the SWS/REM sleep ratio is in favor 
of SWS.
 Rather, following the second hypothesis, patients with 
RLS should show increased light sleep. Though not sta-
tistically significant, as the data in  table 3 suggest, this 
was also the case in the present study, supporting previ-
ous research  [21, 22] . The reason why these mean differ-
ences were statistically not significant remains undis-
closed, though one might speculate that the high stan-
dard deviations within and between the groups (see 
 table 3 ) may have led to descriptively, though not statisti-
cally, significant different means.
 Taken together, the present data confirm the obser-
vation that RLS is a distressing sensorimotor disorder 
which impairs the onset and continuity of sleep (cf.  [8, 
14, 15] ) and that an underlying neuroendocrine mecha-
nism leading to RLS-specific sleep patterns seems rather 
unlikely.
 Our third hypothesis was also confirmed: patients 
with RLS and DS were more likely to be medically pre-
treated with antidepressants than patients with RLS only. 
Given that DS and RLS symptoms have a high degree of 
overlap and that RLS is ‘the most common disorder you 
never heard of ’  [7] , we hold that this finding is of par-
ticular concern for various reasons. First, DS may have 
been erroneously perceived as indicative of the target dis-
ease while the underlying RLS remained undetected. Sec-
ond, there is some evidence that antidepressants such as 
fluoxetine and SSRIs may increase PLMs and conse-
quently also RLS (for detailed discussion, see Picchietti 
and Winkelman  [8] , and Rottach et al.  [33] ). However, in 
this respect, recent findings suggest that the occurrence 
and duration of SSRI-induced RLS symptoms and PLM 
are more complex  [33] . Furthermore, Ulfberg et al. could 
not affirm that people affected by RLS were more often 
consumers of antidepressant medication  [9] . Third, our 
results are in line with findings which highlight that suc-
cessful treatment of RLS also leads to reduced symptoms 
of depression (cf.  [24] ).
 The aim of the explorative approach was to detect if 
along with RLS the diagnosis of concomitant DS may lead 
to differences in objectively assessed sleep patterns. How-
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disorders differed from RLS patients without DS neither 
in the PLM index and arousals nor in sleep. Thus, the data 
suggest that DS concomitant to RLS have no additive ef-
fects, that is to say: DS neither deteriorated nor attenu-
ated the sleep of patients with RLS. The underlying neu-
roendocrine mechanisms could not be assessed, though 
one might speculate that the DS were not associated with 
an alteration in the hypothalamic-pituitary-adrenocorti-
cal axis activity such as to impact sleep in patients with 
RLS.
 Limitations 
 Several considerations warrant against overgeneral-
ization of the findings. First, because patients were re-
cruited from only 1 study center, a systematic bias may 
not be excluded. Second, the samples themselves (de-
scriptive gender distribution; medication intake) may not 
conclusively represent objective sleep variables, though 
virtually no sample of patients may fully represent the 
entire range of disorders. Importantly, intake of a wide 
range of medication prior to referral to an SRU and prior 
to objective sleep assessment is a clinical reality. For the 
present study, we did not find any medication-related bi-
ases in the sleep data despite thorough statistical check-
ing, and it could be added that trimipramine has been 
found not to affect REM sleep  [34] , though another study 
reported increased REM sleep and decreased SWS with 
trimipramine  [35] . Third, the findings showed that the 
groups with RLS and RLS + DS did not differ with respect 
to objectively assessed sleep variables, though they did 
vary with respect to symptoms. Importantly, even though 
it was impossible to assess what patients had said to their 
primary-care physicians before being referred to our 
SRU, it seems that they must have triggered different 
treatment rationales  [36] . Fourth, expert ratings were 
made according to DSM-IV-diagnosed criteria for DS, 
but no self-reported assessment of depressive and anxiety 
symptoms was included. Future research should consider 
self-reports. Fifth, the small sample sizes of the different 
groups may have prevented us from detecting further 
group differences. In this view, though not statistically 
significant even if introduced as a covariate in the present 
study, issues related to gender distribution should always 
be taken into account. Sixth, the cross-sectional design 
did not allow us to draw any conclusions about the direc-
tion and the mechanisms of influence: whereas it has 
been repeatedly found that RLS may lead to mood and 
affective disorders (cf.  [7–11] ), one might also speculate 
about a dopamine deficit which may cause both RLS, DS 
and depressive disorders (cf.  [37] ).
 Conclusions 
 Objectively assessed sleep results show that RLS dra-
matically reduces sleep, even if compared to the sleep of 
patients suffering from MDD. No differences in sleep, 
PLM and arousal were found between RLS patients with 
or without DS. However, RLS patients were 20 times more 
likely to receive unfavorable first-line medication with 
antidepressants if they exhibited concomitant DS. This is 
of particular concern, since 81% of the RLS patients in an 
epidemiological study indicated they referred their com-
plaints to a primary-care physician, but only 6.2% were 
given the diagnosis of RLS  [38, 39] , yet procedures for 
treatment of RLS have been successfully established  [40] . 
Future research might emphasize possible favorable fac-
tors such as regular daytime activities (cf.  [41, 42] ) and 
might follow up pharmacological treatment of RLS with 
respect to treatment outcome, daily functioning and 
quality of life.
 Acknowledgements 
 We thank Alexandre Mueller and Martin Walde for data en-
try. Next, we are grateful to Marielle König and Vladimir Djurd-
jevic, who handled the technical equipment and the polysomno-
graphic scoring. We also thank Nick Emler (Surrey, UK) for 
proofreading the manuscript. Furthermore, we thank Lundbeck 
(Switzerland) for financial support in the form of an unrestricted 
grant (S.B.). Lundbeck had no influence on the study project, in 
particular not concerning data collection, data entry, data analy-
ses, the interpretation of the data or the writing and the submis-
sion of the manuscript or the journal chosen for possible publica-
tion.
 
 References  1 Banks S, Dinges DF: Behavioral and physio-
logical consequences of sleep restriction. J 
Clin Sleep Med 2007; 3: 519–528. 
 2 Curcio G, Ferrara L, De Gennaro M: Sleep 
loss, learning capacity and academic perfor-
mance. Sleep Med Rev 2006; 10: 323–337. 
 3 Roberts ER, Roberts CR, Duong HT: Chron-
ic insomnia and its negative consequences 
for health and functioning of adolescents:
a 12-month prospective study. J Adolesc 
Health 2008; 42: 294–302. 
 4 Morin CM, LeBlanc M, Daley M, Gregoire 
JP, Mérette C: Epidemiology of insomnia: 
prevalence, self-help treatments, consulta-
tions, and determinants of help-seeking be-
haviors. Sleep Med 2006; 7: 123–130. 
 5 Ohayon MM: Epidemiology of insomnia: 
what we know and what we still need to 


























   
   
   
   





















 Brand /Lehtinen /Hatzinger /
Holsboer-Trachsler 
Neuropsychobiology 2010;61:41–4848
 30 Lauer C, Riemann D, Wiegand M, Berger M: 
From early to late adulthood: changes in 
EEG sleep of depressed patients and healthy 
volunteers. Biol Psychiatry 1991;  29:  979–
993. 
 31 The Atlas Task Force: Recording and scoring 
leg movements. Sleep 1993; 16: 748–759. 
 32 Diehl JM, Arbinger R: Einführung in die In-
ferenzstatistik (Introduction to inferential 
statistics). Eschborn bei Frankfurt am Main, 
Klotz, 2001. 
 33 Rottach KG, Schner BM, Kirch MH, Zivotof-
sky AZ, Teufel LM, Gallwitz T, Messer T: 
Restless legs syndrome as side effects of sec-
ond generation antidepressants. J Psychiatr 
Res 2008; 43: 70–75. 
 34 Wiegand M, Berger M, Zulley J, von Zerssen 
D: The effect of trimipramine on sleep in pa-
tients with major depressive disorder. Phar-
macopsychiatry 1986; 19: 198–199. 
 35 Sonntag A, Rothe B, Guldner J, Yassouridis 
A, Holsboer F, Steiger A: Trimipramine and 
imipramine exert different effects on the 
sleep EEG and on nocturnal hormone secre-
tion during treatment of major depression. 
Depression 1996; 4: 1–13. 
 36 Kushida CA: Clinical presentation, diagno-
sis, and quality of life issues in restless legs 
syndrome. Am J Med 2007; 120:S4–S12. 
 37 Pania L, Gessab GL: Dopaminergic deficit 
and mood disorders. Int Clin Psychophar-
macol 2002;17(suppl 4):S1–S7. 
 38 Hening W, Walters AS, Allen RP, Mont-
plaisier J, Myers A, Ferini-Strambi L: Impact, 
diagnosis and treatment of restless legs syn-
drome (RLS) in a primary care population: 
the REST (RLS epidemiology, symptoms, 
and treatment) primary care study. Sleep 
Med 2004; 5: 237–246. 
 39 Chaudhuri KR, Forbes A, Grosset D, Lees A, 
Shneerson J, Schapira A, Stillman P, Wil-
liams, A: Diagnosing restless legs syndrome 
(RLS) in primary care. Curr Med Res Opin 
2004; 20: 1785–1795. 
 40 Hening WA: Current guidelines and stan-
dards of practice for restless legs syndrome. 
Am J Med 2007; 120:S22–S27. 
 41 Biddle SJH, Mutrie N: Psychology of Physi-
cal Activity. Determinants, Well-Being and 
Interventions (ed 2). London, Routledge, 
2008. 
 42 Faulkner GEJ, Taylor AH: Exercise, Health 
and Mental Health. Emerging Relationships. 
London, Routledge, 2005. 
 
 6 Allen RP, Picchietti D, Hening WA, Trenk-
walder C, Walters AS, Montplaisir J: Restless 
legs syndrome: diagnostic criteria, special 
considerations and epidemiology: a report 
from the restless legs syndrome diagnosis and 
epidemiology workshop at the National Insti-
tutes of Health. Sleep Med 2003; 4: 101–119. 
 7 Hornyak M, Kopasz M, Berger M, Riemann 
D, Voderholzer U: Impact of sleep-related 
complaints on depressive symptoms in pa-
tients with restless legs syndrome. J Clin Psy-
chiatry 2005; 66: 1139–1145. 
 8 Picchietti DL, Winkelman J: Restless legs 
syndrome, periodic limb movements in 
sleep, and depression. Sleep 2005; 28: 891–
898. 
 9 Ulfberg J, Bjorrvatn B, Leissner L, Gyring J, 
Karlsborg M, Regeur L, Skeidsvoll H, Polo O, 
Partinen M: Comorbidity in restless legs 
syndrome among a sample of Swedish adults. 
Sleep Med 2007; 8: 768–772. 
 10 Winkelmann J, Prager M, Lieb R, Pfister H, 
Spiegel B, Wittchen HU, Holsboer F, Trenk-
walder C, Ströhle A: ‘Anxietas tibiarum’: de-
pression and anxiety disorders in patients 
with restless legs syndrome. J Neurol 2005; 
 252: 67–71. 
 11 Lee HB, Hening WA, Allen RP, Kalaydjian 
AE, Earley CJ, Eaton WW, Lyketsos CG: 
Restless legs syndrome is associated with 
DSM-IV major depressive disorder and pan-
ic disorder in the community. J Neuropsy-
chiatry Clin Neurosci 2008; 20: 101–105. 
 12 Hatzinger M, Hemmeter UM, Brand S, Ising 
M, Holsboer-Trachsler E: Electroencephalo-
graphic sleep profiles in treatment course 
and long-term outcome of major depression: 
association with DEX/DRH-test response. J 
Psych Res 2004; 38:453–465. 
 13 Sethi KD: Restless legs syndrome sees the 
light of day. Lancet Neurol 2008; 7: 564–565. 
 14 Ferini-Strambi L: RLS-symptoms: differen-
tial diagnosis by history and clinical assess-
ment. Sleep Med 2007; 8:S3–S6. 
 15 Hadjigeorgiou GM, Stefanidis I, Dardiotis E, 
Aggellakis K, Sakkas GK, Xiromerisiou G, 
Konitsiotis S, Paterakis K, Poultsidi A, Tsi-
mourtou V, Ralli S, Gourgoulianis K, Zint-
zaras E: Low RLS prevalence and awareness 
in central Greece: an epidemiological survey. 
Eur J Neurol 2007; 14: 1275–1280. 
 16 Winkelman JW: Considering the causes of 
RLS. Eur J Neurol 2006; 13(suppl 3):8–14. 
 17 Allen RP: Finding the dopamine abnormal-
ity in RLS: the iron-dopamine connection 
evaluated in translational research. Sleep 
Med 2007; 8(suppl 1):S17. 
 18 Davidson RJ, Pizzagalli D, Nitschke JB, But-
nam K: Depression: perspectives from affec-
tive neuroscience. Annu Rev Psychol 2002; 
 53: 545–574. 
 19 Beck AT: Depression. Causes and Treatment. 
Philadelphia, University of Pennsylvania 
Press, 1967. 
 20 Lewinsohn PM: A behavioral approach to 
depression; in Friedman RJ, Katz MM (eds): 
The Psychology of Depression. New York, 
Wiley, 1974. 
 21 Coccagna G, Lugaresi E: Restless legs syn-
drome and nocturnal myoclonus. Int J Neu-
rol 1982; 15: 77–87. 
 22 Hornyak M, Feige B, Voderholzer U, Phil-
ipsen A, Riemann D: Polysomnography 
findings in patients with restless legs syn-
drome and in healthy controls: a compara-
tive observational study. Sleep 2007; 30: 861–
865. 
 23 Barrière G, Cazalets JR, Bioulac B, Tison F, 
Ghorayeb I: The restless legs syndrome. Prog 
Neurobiol 2005; 77: 139–165. 
 24 Saletu M, Anderer P, Saletu-Zyhlarz G,
Hauer C, Saletu B: Acute placebo-controlled 
sleep laboratory studies and clinical follow-
up with pramipexole in restless legs syn-
drome. Eur Arch Psychiatry Clin Neurosci 
2002; 252: 185–194. 
 25 American Psychiatric Association: Diagnos-
tic and Statistical Manual of Mental Disor-
ders (ed 4). Washington, American Psychiat-
ric Association, 2000. 
 26 Wittchen HU, Zaudig M, Schramm E,
Spengler P, Mombour W, Klug J, Horn R: 
Strukturiertes klinisches Interview für 
DSM-III-R. Deutschsprachige, erweiterte 
Bearbeitung der amerikanischen Original-
version des SCID von R.L. Spitzer, J.B.W. 
Williams, M. Gibbon. Weinhein, Beltz-Test, 
1987. 
 27 Walters AS, International Restless Legs Syn-
drome Study Group: Toward a better defini-
tion of the restless legs syndrome. Mov Dis-
ord 1995; 10: 634–642. 
 28 Schapira AHV: RLS patients: who are they? 
Eur J Neurol 2006; 14(suppl 3):2–7. 
 29 Rechtschaffen A, Kales A: A manual of stan-
dardized terminology techniques and scor-
ing system for sleep stages of human sub-
jects. Bethesda, US Department of Health, 
Education and Welfare, Neurological Infor-


























   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 2
:1
3:
29
 P
M
